about
A novel member of the leukocyte receptor complex regulates osteoclast differentiationFeedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivoExpression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-αDown-regulation of Irf8 by Lyz2-cre/loxP accelerates osteoclast differentiation in vitro.Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interactionShared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell developmentPorphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine giSecretion of a truncated osteopetrosis-associated transmembrane protein 1 (OSTM1) mutant inhibits osteoclastogenesis through down-regulation of the B lymphocyte-induced maturation protein 1 (BLIMP1)-nuclear factor of activated T cells c1 (NFATc1) axMonocarboxylate transporter-1 is required for cell death in mouse chondrocytic ATDC5 cells exposed to interleukin-1beta via late phase activation of nuclear factor kappaB and expression of phagocyte-type NADPH oxidase.Induction of osteoblastic differentiation of neural crest-derived stem cells from hair folliclesSmad4 is required to inhibit osteoclastogenesis and maintain bone mass.Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis.IFN-gamma down-regulates Secretoglobin 3A1 gene expression.Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis.Expression of nephronectin is enhanced by 1α,25-dihydroxyvitamin D3.Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor κB (RANK) Signaling Complex Enhances Osteoclastogenesis.Bropirimine inhibits osteoclast differentiation through production of interferon-β.Expression of nephronectin is inhibited by oncostatin M via both JAK/STAT and MAPK pathwaysD-chiro-inositol negatively regulates the formation of multinucleated osteoclasts by down-regulating NFATc1.Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.Interleukin-1beta induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner.Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts.Conditional deletion of CD98hc inhibits osteoclast development.R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclastsReceptor activator of NF-kappaB ligand induces the fusion of mononuclear preosteoclasts into multinucleated osteoclasts.Microscopic study on resorption of β-tricalcium phosphate materials by osteoclasts.Downregulation of carbonic anhydrase IX promotes Col10a1 expression in chondrocytes.Nephronectin expression is regulated by SMAD signaling in osteoblast-like MC3T3-E1 cells.Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL.Differentiation and function of osteoclasts cultured on bone and cartilage.Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns.LPS administration increases CD11b+ c-Fms+ CD14+ cell population that possesses osteoclast differentiation potential in mice.In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.Localization and osteoblastic differentiation potential of neural crest-derived cells in oral tissues of adult mice.Destruxins, cyclodepsipeptides, block the formation of actin rings and prominent clear zones and ruffled borders in osteoclasts.Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophagesOsteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production
P50
Q24675157-F95814E8-FC6A-427A-B08A-C9BB3005F0D5Q26863571-73A2F593-FA8C-40C2-8EF3-C92E5EDB6BD9Q28191731-13BC9B2B-3908-4131-A7F9-A8EA20050C93Q28594623-F7B06805-E38B-4EAB-AFFC-652EED2212ABQ33770027-DECF8F47-9AFB-4126-B87A-590916039280Q33886695-4019232C-ACC5-474F-A798-37DAFC1974BCQ34049333-6DE695C5-1C31-472C-8851-6037A3299DB7Q34076000-F1911C65-DE83-4912-9445-374FF152DEE7Q34774474-C890BBCF-052A-4E10-AF2B-F9DE29EA0F2DQ34869339-0E330A06-FC01-4F0B-8EAD-ED878889EA24Q36338215-1327D400-728D-45FA-BDA5-BFAB105FBD25Q37330422-A3169DEB-B7EF-481C-8345-66FCFC50A9F7Q37370702-BC342792-693F-4FB3-909D-8B560B80BC98Q37471952-2C76A972-CE24-40E0-B12A-5E41D27763FBQ38363249-74B0DD44-EF79-4AA1-88D4-CEB6A473E34DQ38745342-48EB5D95-93CB-499E-8BEB-63ED3240D499Q38752770-117370D0-D600-4E4D-9A9F-418B241B4272Q38833066-E6503094-247E-4CC4-824B-E0351D559CFDQ38883236-A1D535F8-5DAA-4E0E-BA7D-B01D23620428Q39328894-2646DD39-7721-49AB-83B0-28A82AD70D63Q39505996-7A9A5041-44B3-4305-ADF3-C506077CA77BQ40443689-56C85249-B656-46B9-B9AC-ACE0486C2737Q40496789-8D0731FE-DA64-4B19-8671-62513B4C3CADQ40960288-85D3F4A4-86A5-404F-8DDE-A82432CF1621Q41683401-1C13F93C-1A0C-47BA-8B72-77256F4B07DCQ41827206-0AD9C77F-A9C0-4B3D-AD1E-FA900A12147FQ41850870-057AAE98-42FC-4128-8EA9-65366AB017EDQ41985170-09C8F00B-F719-4927-9470-9632D152F7A8Q42592226-EAC0F770-C968-47CA-8000-74E17ACFB9FAQ42832323-7FAF0E0C-7DC8-4CAA-95F5-ACF6FCFA5582Q42860795-F4DA3B44-DF5D-4A3C-AEFC-6FE7420B8BBCQ43864464-56A66781-D673-4E0E-AC3F-7DAF31810F82Q46282243-70C8CCE1-7EEB-43CC-B758-7DF6F19ADA62Q46303298-09D4127A-1E51-47C7-890D-695306C2E165Q48250265-14CBC385-9573-4C62-AAEA-2D6FE231C825Q49843242-03129D0E-A14F-4EC2-B391-C67CA74A000CQ50251433-60FDF5D5-1EB5-4261-9062-C648034190D1Q52551920-D20809E0-71D1-46D6-803F-80844A1D66FCQ73149209-EE2558C7-0032-4C32-90B7-BE4A531500F0Q73203728-7792152E-6805-46B5-B896-277BBD717819
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Masamichi Takami
@ast
Masamichi Takami
@en
Masamichi Takami
@es
Masamichi Takami
@nl
Masamichi Takami
@sl
type
label
Masamichi Takami
@ast
Masamichi Takami
@en
Masamichi Takami
@es
Masamichi Takami
@nl
Masamichi Takami
@sl
prefLabel
Masamichi Takami
@ast
Masamichi Takami
@en
Masamichi Takami
@es
Masamichi Takami
@nl
Masamichi Takami
@sl
P106
P108
P1153
7102741076
P31
P496
0000-0002-4506-3975